Afficher la notice abrégée

Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.

dc.rights.licenseopenen_US
dc.contributor.authorWHITTAM, Daniel H
dc.contributor.authorCOBO-CALVO, Alvaro
dc.contributor.authorLOPEZ-CHIRIBOGA, A Sebastian
dc.contributor.authorPARDO, Santiago
dc.contributor.authorGORNALL, Matthew
dc.contributor.authorCICCONI, Silvia
dc.contributor.authorBRANDT, Alexander
dc.contributor.authorBEREK, Klaus
dc.contributor.authorBERGER, Thomas
dc.contributor.authorJELCIC, Ilijas
dc.contributor.authorGOMBOLAY, Grace
dc.contributor.authorOLIVEIRA, Luana Micheli
dc.contributor.authorCALLEGARO, Dagoberto
dc.contributor.authorKANEKO, Kimihiko
dc.contributor.authorMISU, Tatsuro
dc.contributor.authorCAPOBIANCO, Marco
dc.contributor.authorGIBBONS, Emily
dc.contributor.authorKARTHIKEAYAN, Venkatraman
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorBROCHET, Bruno
dc.contributor.authorAUDOIN, B.
dc.contributor.authorMATHEY, Guillaume
dc.contributor.authorLAPLAUD, David
dc.contributor.authorTHOUVENOT, Eric
dc.contributor.authorCOHEN, Mikaël
dc.contributor.authorTOURBAH, Ayman
dc.contributor.authorMAILLART, Elisabeth
dc.contributor.authorCIRON, Jonathan
dc.contributor.authorDESCHAMPS, Romain
dc.contributor.authorBIOTTI, Damien
dc.contributor.authorROSTASY, Kevin
dc.contributor.authorNEUTEBOOM, Rinze
dc.contributor.authorHEMINGWAY, Cheryl
dc.contributor.authorFORSYTH, Rob
dc.contributor.authorMATIELLO, Marcelo
dc.contributor.authorWEBB, Stewart
dc.contributor.authorHUNT, David
dc.contributor.authorMURRAY, Katy
dc.contributor.authorHACOHEN, Yael
dc.contributor.authorLIM, Ming
dc.contributor.authorLEITE, M Isabel
dc.contributor.authorPALACE, Jacqueline
dc.contributor.authorSOLOMON, Tom
dc.contributor.authorLUTTEROTTI, Andreas
dc.contributor.authorFUJIHARA, Kazuo
dc.contributor.authorNAKASHIMA, Ichiro
dc.contributor.authorBENNETT, Jeffrey L
dc.contributor.authorPANDIT, Lekha
dc.contributor.authorCHITNIS, Tanuja
dc.contributor.authorWEINSHENKER, Brian G
dc.contributor.authorWILDEMANN, Brigitte
dc.contributor.authorSATO, Douglas Kazutoshi
dc.contributor.authorKIM, Su-Hyun
dc.contributor.authorHUDA, Saif
dc.contributor.authorKIM, Ho Jin
dc.contributor.authorREINDL, Markus
dc.contributor.authorLEVY, Michael
dc.contributor.authorJARIUS, Sven
dc.contributor.authorTENEMBAUM, Silvia
dc.contributor.authorPAUL, Friedemann
dc.contributor.authorPITTOCK, Sean
dc.contributor.authorMARIGNIER, Romain
dc.contributor.authorJACOB, Anu
dc.date.accessioned2024-10-16T07:52:31Z
dc.date.available2024-10-16T07:52:31Z
dc.date.issued2020-09-01
dc.identifier.issn2211-0356en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/202521
dc.description.abstractEnTo assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD). Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model). Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3-14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3-24.9) months. In this 'relapsing group', relapse rate declined by 37% (95%CI=19-52%, p<0.001) overall, 63% (95%CI=35-79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2-44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses. RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results.
dc.language.isoENen_US
dc.subject.enMyelin oligodendrocyte glycoprotein
dc.subject.enMOG
dc.subject.enRituximab
dc.subject.enNeuromyelitis optica
dc.subject.enOptic neuritis
dc.title.enTreatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.
dc.title.alternativeMult Scler Relat Disorden_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.msard.2020.102251en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed32629363en_US
bordeaux.journalMultiple Sclerosis and Related Disordersen_US
bordeaux.page102251en_US
bordeaux.volume44en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamRelations glie-neuroneen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Multiple%20Sclerosis%20and%20Related%20Disorders&amp;rft.date=2020-09-01&amp;rft.volume=44&amp;rft.spage=102251&amp;rft.epage=102251&amp;rft.eissn=2211-0356&amp;rft.issn=2211-0356&amp;rft.au=WHITTAM,%20Daniel%20H&amp;COBO-CALVO,%20Alvaro&amp;LOPEZ-CHIRIBOGA,%20A%20Sebastian&amp;PARDO,%20Santiago&amp;GORNALL,%20Matthew&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
MAGENDIE_MultSclerRelatDisord_ ...
Taille:
1.104Mo
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée